Dominion Aesthetic Technologies, Inc. and BellaMia Technologies, Inc. have completed a $200 million strategic merger, creating a larger medical aesthetics company focused on laser-based and robotic treatment platforms. The newly combined business will operate under the BellaMia Technologies name and bring together two device portfolios addressing body contouring and skin rejuvenation. The transaction positions the company to compete more aggressively in a medical aesthetics market increasingly shaped by automation, precision energy delivery, and demand for less invasive treatment options.
A Combined Platform for Aesthetic Physicians
Dominion is best known for EON, a non-contact robotic laser platform developed for targeted fat reduction and body contouring. BellaMia created The Botticelli, an all-in-one laser platform designed for skin rejuvenation and intended to give physicians access to key laser wavelengths in a compact practice-friendly system. By combining these technologies, the merged company aims to offer aesthetic practices a broader device portfolio spanning both contouring and skin treatment.
Leadership and Strategic Direction
Janet Campbell will serve as chief executive officer of the combined company, bringing together the founder, inventor, and management teams from both businesses. In the announcement, Campbell emphasized that the two companies were built around a shared goal of giving physicians practical tools designed around innovation, simplicity, and unmet clinical needs. The company expects the merger to support faster product development, a wider commercial footprint, and more efficient operations across engineering, marketing, and physician support.
Technology and Market Positioning
Cooper Collins, executive chairman of BellaMia Technologies, described the merger as debt-free and said it strengthens the company’s capabilities in artificial intelligence, robotics, sensors, and engineering. Those areas are becoming more important across aesthetic medicine as providers look for systems that can improve consistency, workflow, and treatment planning. The combined business said it intends to use shared expertise in robotics, lasers, and AI-enabled treatment optimization to expand its product portfolio globally.
Clinical and Operational Footprint
Michael R. Davis, chief medical officer of BellaMia Technologies, said the combined portfolio will support a Center of Excellence for the company’s technologies. He highlighted The Botticelli’s precision and versatility for skin-focused procedures, while noting that EON expands treatment options for targeted fat reduction. The company also pointed to demand from fit patients seeking refinement and from patients experiencing GLP-1-associated weight loss who may need advanced body contouring solutions.
The merger gives BellaMia Technologies a larger platform at a time when aesthetic practices are weighing investment in devices that combine clinical utility with workflow efficiency. While the announcement does not disclose detailed integration timelines, the strategic logic centers on combining complementary products, shared technical capabilities, and a broader physician-support infrastructure. If executed effectively, the transaction could strengthen BellaMia’s position in the medical aesthetics device sector and accelerate its ambitions in robotic, laser, and AI-assisted treatment technologies.